# Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry - FDA Guidance Document

Source: https://www.keypedia.com/guidances/guidance-document/severely-debilitating-or-life-threatening-hematologic-disorders-nonclinical-development-of-pharmaceuticals-guidance-for-industry/e5cdf45b-9688-49a6-8496-614c702750aa

> FDA guidance document: Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry. Issue date: March 15, 2019. Get complete insights and analysis.

---

## Details

- Title: Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-03-15
- Last Changed: 2020-04-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-1328">FDA-2018-D-1328</a>

## Related Documents

- [Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/oncology-therapeutic-radiopharmaceuticals-nonclinical-studies-and-labeling-recommendations-guidance-for-industry/207c1c32-d577-4283-836d-ae7bb8e1ea92)
- [Osteoporosis:  Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry:  Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/osteoporosis-nonclinical-evaluation-of-drugs-intended-for-treatment-guidance-for-industry-guidance-for-industry/8305ef9e-7edf-412b-bb46-28ef3a7f9493)
- [Testicular Toxicity: Evaluation During Drug Development](https://www.keypedia.com/guidances/guidance-document/testicular-toxicity-evaluation-during-drug-development/04182421-d0d9-46c1-ac57-10b10ca62d0c)